Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 835.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 24.49%
• EPS Growth: 5.14%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 66,394,240
• 10 Day Avg. Volume: 763,766
• 30 Day Avg. Volume: 835,782
• PEG Ratio: -1.98
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.68
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 38.01
• Enterprise Value/Gross Profit: 257.57
• Enterprise Value/Ebitda: -1.78
• 1Y Price Target: $59.78
• Price Target Upside: 204.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

Celldex's robust equity stability and low leverage are offset by persistent negative profitability and cash flows, resulting in a moderate financial performance score. Technical analysis shows mild upward momentum, but longer-term trends remain challenging. Valuation is a concern with a negative P/E ratio and no dividend yield, reflecting ongoing profitability challenges typical of the biotechnology industry.

Positive Factors

Clinical Data

Barzolvolimab demonstrates an attractive balance of efficacy and safety with long-term treatment.

Clinical Development

Barzolvolimab holds the most compelling clinical profile to date across two large Phase 2 urticaria studies, and is meaningfully ahead of competitors with enrollment well underway in the Phase 3 EMBARQ trials.

Financial Stability

Celldex ended the quarter with $673.3 million in cash, which management believes should fund all ongoing operations through 2027.

Negative Factors

Clinical Uncertainty

The update on 76-week Ph2 data in CSU is seen as a moderate driver of sentiment unless on-target side effects persist.

Competitive Landscape

Attention is increasingly turning toward Ph2 data in EoE, which could be a significant factor influencing sentiment.

Market Perception

Moving the barzol conversation toward mast-cell driven indications with greater unmet need than CU could bolster CDLX sentiment.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

How the Company Makes Money

Celldex makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include upfront and milestone payments from strategic collaborations and partnerships with other pharmaceutical companies, as well as potential royalties from successfully marketed products resulting from these partnerships. Additionally, the company may generate income from government grants and research funding aimed at supporting its innovative therapeutic programs. As Celldex advances its drug candidates through clinical trials and obtains regulatory approvals, it aims to generate revenue from product sales and licensing agreements.

Celldex Financial Statement Overview

Summary

Celldex exhibits robust equity stability and low leverage, which are strong points in its financial profile. However, persistent operating losses and negative cash flows indicate significant challenges in achieving profitability. Continued investment in growth opportunities could improve long-term prospects, but current financial performance reflects the typical volatility and risk associated with the biotechnology sector.

Income Statement

The company's revenue has shown some growth over the years, with a notable increase from 2022 to 2023. However, the consistent negative EBIT and net income margins highlight ongoing profitability challenges. The gross profit margin is positive, but the net income remains negative, indicating high operational costs relative to revenue.

Balance Sheet

Celldex has maintained a strong equity position with a high equity ratio, suggesting financial stability. The debt-to-equity ratio is low, indicating limited leverage. However, the persistent negative net income impacts the return on equity, reflecting challenges in generating shareholder value.

Cash Flow

The operating cash flow has been negative, indicating challenges in generating cash from core operations. Despite this, the company has managed to maintain liquidity through financing activities. Free cash flow remains negative, aligning with the company's continued investment in growth and development.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.02M	6.88M	2.36M	4.65M	7.42M
	Gross Profit
3.84M	3.88M	957.00K	1.58M	-35.12M
	EBIT
-195.08M	-154.54M	-115.23M	-71.24M	-63.35M
	EBITDA
-154.69M	-139.03M	-104.20M	-66.08M	-45.64M
	Net Income Common Stockholders
-157.86M	-141.43M	-122.78M	-70.51M	-59.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
725.28M	423.60M	304.95M	408.25M	194.42M
	Total Assets
792.34M	465.63M	352.74M	444.65M	235.84M
	Total Debt
3.81M	2.54M	4.03M	3.04M	3.48M
	Net Debt
-24.54M	-32.27M	-25.40M	-36.10M	-40.35M
	Total Liabilities
45.34M	36.46M	26.53M	25.18M	26.48M
	Stockholders Equity
747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow		Free Cash Flow
-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
	Operating Cash Flow
-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
	Investing Cash Flow
-290.13M	-105.78M	89.94M	-216.16M	-98.22M
	Financing Cash Flow
441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.62
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 19.62 is above the 20-day moving average (MA) of 19.56, above the 50-day MA of 19.19, and below the 200-day MA of 26.94, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 51.44 is Neutral, neither overbought nor oversold. The STOCH value of 44.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	71 Outperform	$910.93M	14.00	21.57%	―	25.92%	―
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
CLDX	52 Neutral	$1.34B	―	-23.20%	―	24.49%	5.14%
SNDX	48 Neutral	$945.66M	―	-93.70%	―	―	-25.83%
WVE	47 Neutral	$1.02B	―	-105.50%	―	-7.06%	-57.17%
DYN	43 Neutral	$1.43B	―	-64.01%	―	―	14.93%
IOVA	41 Neutral	$644.49M	―	-51.85%	―	11070.12%	32.07%